Hovione, a global Contract Development and Manufacturing Organization (CDMO), has completed a significant expansion of its East Windsor, New Jersey, manufacturing site, marking a strategic move to bolster its U.S. operations and enhance its integrated drug manufacturing capabilities. This multi-million-dollar investment cycle underscores the company’s commitment to advancing its technological infrastructure and aligning with the growing demand for sustainable, high-quality pharmaceutical production.
The initial phase of the expansion includes a 31,000-square-foot building designed to house two size-3 spray dryers (PSD-3), a critical technology for producing amorphous solid dispersions (ASDs). This investment more than doubles Hovione’s spray drying capacity in the United States, a move that will significantly enhance the company’s ability to develop and manufacture ASDs—solutions that improve drug solubility and bioavailability. Construction is already underway, with Good Manufacturing Practice (GMP) operations slated to commence in the second quarter of 2026.
Jean-Luc Herbeaux, Ph.D., CEO of Hovione, emphasized the strategic importance of this expansion: “Since launching our New Jersey operations in 2002, Hovione has been one of the longest established European CDMOs in the United States. This investment reinforces Hovione’s leadership in spray drying—a core technology platform where we have built extensive know-how and capabilities. By continuing to advance our platforms and expand capacity in the U.S., we are strengthening the foundation that enables our partners to bring complex medicines to patients more efficiently.”
The expansion is not just about increasing production capacity; it’s about integrating cutting-edge technology with sustainable design. The new facilities will incorporate the latest advancements in pharmaceutical manufacturing, including continuous and batch tableting capabilities, as well as digital innovations that enhance quality control and research and development (R&D) processes. Hovione has also acquired additional adjacent land to support future growth, ensuring the East Windsor site remains at the forefront of evolving customer needs.
David Basile, Vice President of Technical Operations – Americas at Hovione, highlighted the broader implications of this expansion: “This expansion in New Jersey marks a significant step in extending our capabilities in the U.S., which go far beyond machine time or equipment capacity. We are integrating our teams, specialized assets, proprietary technologies, and digital systems to deliver distinctive end-to-end ASD and continuous tableting platforms to our customers. Through our new strategic engagement model, customers can gain privileged access to innovation and assets that accelerate their programs and create long-term value.”
This initiative is part of Hovione’s broader international growth strategy, which includes capacity investments in Ireland and Portugal. Together, these efforts will create a network of autonomous sites that span the development and commercialization of APIs, drug product intermediates, and drug products, all under harmonized quality systems.
For drug developers seeking to expand U.S. manufacturing capacity, gain strategic access to critical assets, or achieve an expedited pathway to filing and commercialization, Hovione’s expansion presents a compelling opportunity. The company invites potential collaborators to explore how its enhanced capabilities can support their goals at www.hovione.com/contact-us.
As the pharmaceutical industry continues to evolve, Hovione’s strategic investments in technology, sustainability, and capacity reflect a forward-thinking approach to meeting the demands of a rapidly changing market. This expansion not only strengthens Hovione’s position as a leader in pharmaceutical manufacturing but also sets a new standard for innovation and efficiency in the sector.